Petros Ligoxygakis
LigoxygakisLab
The evidence on the new SARS-CoV2 variant considered by NervTag was 1) growth rate from genomic data (increased growth rate); 2) studies of R-values and detection of the variant (suggested
Read more
By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.